Fig. 5: Inhibition of candidate genes sensitizes tumors to T cell cytotoxicity. | Nature Communications

Fig. 5: Inhibition of candidate genes sensitizes tumors to T cell cytotoxicity.

From: CRISPR activation screen identifies BCL-2 proteins and B3GNT2 as drivers of cancer resistance to T cell-mediated cytotoxicity

Fig. 5: Inhibition of candidate genes sensitizes tumors to T cell cytotoxicity.

a Cell survival against HER2 CAR T cell cytotoxicity in SW1417 (HER2+) colorectal adenocarcinoma with different candidate genes knocked down using CRISPRi and 2 sgRNAs per gene. KD, knockdown. NT non-targeting. b–e Cell survival against T cell cytotoxicity in tumor cells treated with MCL1 or B3GNT2 small-molecule inhibitors, S63845 and kifunensine, respectively. Heatmaps show the significance of statistical analyses for each condition. b A375 (NY-ESO-1+, HLA-A2+) melanoma against ESO T cells. c SW1417 (HER2+) colorectal adenocarcinoma against HER2 CAR T cells. d CCLF_MELM_0011_T (AXL+) primary patient-derived melanoma model against AXL CAR T cells. e CCLF_PANC_0014_T (HER2+) primary patient-derived pancreatic adenocarcinoma against HER2 CAR T cells. All values are mean ± s.e.m with n = 8. ns not significant. Two-tailed t tests with adjustments for multiple comparisons were performed. Source data are provided in Source Data 5.

Back to article page